How does the safety profile of Dato-DXd influence its use in patients with comorbidities or frailty compared to standard chemotherapy?

There were fewer high-grade adverse events seen with Dato-DXd compared to investigator’s choice chemotherapy (20% vs. 45%, respectively), though we do see higher rates of nausea, stomatitis, fatigue, alopecia, and dry eyes or keratitis with Dato-DXd compared to chemotherapy. With the use of prophyla...

Dato-DXd offers a more tolerable safety profile compared to standard chemotherapy, making it a reasonable option for patients with comorbidities or frailty. In TROPION-Breast01, it demonstrated reduced rates of neutropenia, diarrhea, and alopecia, though stomatitis remains common and requires proact...